Physician profile
Frederick Kinder
NPI 1326030016
$5,693.75
in general payments reported to CMS, 2019-2025
40 companies · $943 in 2025
The $943 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $442 · 2021: $884 · 2022: $909 · 2023: $1,209 · 2024: $628 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $805.82 | 2019-2025 | |
| Currax Pharmaceuticals LLC | $343.75 | 2020-2024 | Contrave |
| Astellas Pharma US INC | $334.89 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $333.58 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $332.66 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $302.45 | 2023-2025 | Myfembree |
| Shield Therapeutics INC | $297.63 | 2022-2025 | Accrufer |
| Avion Pharmaceuticals | $283.13 | 2019-2023 | Balcoltra |
| Sage Therapeutics, LLC | $270.44 | 2019-2025 | Zurzuvae |
| Exeltis, USA INC. | $260.02 | 2021-2025 | Slynd |
| Organon LLC | $241.75 | 2021-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $210.39 | 2023-2025 | |
| Novo Nordisk INC | $189.51 | 2019-2025 | Wegovy |
| Aspira Women'S Health INC | $174.42 | 2021-2022 | |
| Evofem Biosciences, INC. | $158.45 | 2021-2025 | Phexxi, Solosec, Phexx |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Kinder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.